Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study.
Shares in Amylyx Pharma slid today after the FDA published a less-than-enthusiastic assessment of its amyotrophic lateral sclerosis (ALS) therapy ahead of an advisory committee meeting on W
Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights outside the US to Biohaven's Nurtec ODT, an oral therapy for migraine.
Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a "safety signal" in the study.
Danish drugmaker Lundbeck has teamed up with Inscopix – the developer of a technology that can film neurons in the brain in real time – to try to find new drugs for central nervous system d
Just a few months ago, Amylyx was talking about having to complete another clinical trial before it could file for FDA approval of its drug for neurodegenerative disease amyotrophic lateral